

Telehealth Check-in Note

PATIENT: Miller, Susan Anne **ID:** SYN154 **DOB:** March 13, 1972

DATE: Nov 02, 2023

PROVIDER: E. Reed, MD, PhD

ENCOUNTER TYPE: Scheduled Telehealth Visit (Video)

INTERVAL HX: Pt ~7 mos into Alectinib 600mg BID for Stage IV ALK+ Lung Adeno (Dx Mar 29, 2023; mets Pleura/Liver). PDL1 <1%. Reports feeling excellent, asymptomatic (ECOG 0). Works full-time. Tolerating Alectinib very well – notes only mild constipation, well controlled w/ Miralax PRN <weekly. No myalgia, edema, LFT issues, vision changes.

STATUS: Awaiting first surveillance scans (CT C/A/P + Brain MRI) scheduled next week. Labs drawn locally last week reviewed - CBC/CMP/LFTs/CPK all WNL.

ASSESSMENT/PLAN: Clinically doing outstandingly well on Alectinib. Continue Alectinib 600mg BID. Follow up after imaging results available next week (plan phone call to discuss results). Schedule next formal f/u visit (telehealth or in-person) in 3 mos. RTC sooner PRN concerns.